| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5578621 | ROMARK | Benzamide derivatives |
Sep, 2014
(9 years ago) | |
| US6020353 | ROMARK | 2-(hydroxy)-N-(5-nitro-2-thiazolyl) benzamide |
Sep, 2014
(9 years ago) | |
| US6117894 | ROMARK | Acid stabilized pharmaceutical compositions of tizoxanide and nitazoxanide |
May, 2017
(6 years ago) | |
| US5968961 | ROMARK | Pharmaceutical compositions of tizoxanide and nitazoxanide |
May, 2017
(6 years ago) | |
| US5965590 | ROMARK | Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide |
Jul, 2017
(6 years ago) | |
Alinia is owned by Romark.
Alinia contains Nitazoxanide.
Alinia has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Alinia are:
- US5578621
- US6020353
- US6117894
- US5968961
- US5965590
Alinia was authorised for market use on 21 July, 2004.
Alinia is available in tablet;oral, for suspension;oral dosage forms.
Alinia can be used as method of treating parasitic infections, method of treating infection by cryptosporidium parvum in an immunocompromised mammal.
The generics of Alinia are possible to be released after 03 July, 2017.
Drugs and Companies using NITAZOXANIDE ingredient
Market Authorisation Date: 21 July, 2004
Treatment: Method of treating parasitic infections; Method of treating infection by cryptosporidium parvum in an immunocompromised mammal
Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL
ALINIA family patents
